Zusammenfassung
Die Dopamin (DA)-Hypothese der Schizophrenie geht von einer Überaktivität dopaminerger Neurone aus, welche durch eine vermehrte Ausschöttung von DA oder eine öberschieβende Reaktion des DA-Rezeptors bedingt sein kann. Die antipsychotische Wirkung der Neuroleptika auf der Grundlage des DA-Antagonismus ist ein wichtiger Beleg för diese Hypothese. Umgekehrt können unter Anwendung von Substanzen, die zu einer vermehrten DA-Ausschiittung föhren, wie beispielsweise Amphetamin, Psychose-ahnliche Zustande beobachtet werden.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, Goldman Rakic PS (1995) Regional, cellular, and subcellular variations in the distribution of Dl and D5 dopamine receptors in primate brain. J Neurosci 15: 7821–7836
Caron M (1996) A dopamine transporter mouse knockout. Am J Psychiatry 153: 1515
Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RSJ, GrAsby PM (1995) Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378: 180–182
Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76
Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordström AL, Hall H, Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 47: 213–219
Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) PET analysis of central D1 and D2 dopamine recepor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49: 538–544
Hitri A, Hurd YL, Wyatt RJ, Deutsch SI (1994) Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin Neuropharmacol 17: 1–22
Huntley GW, Morrison JH, Prikhozhan A, Selfon SC (1992) Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum. Mol Brain Res 15: 181–188
Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466–476
Kilts CD, Anderson CM, Ely TD, Nishita JK (1987) Absence of synthsis modulating nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal populations. J Neurosci 7: 3961–3975
Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze A, Möller HJ, Biersack HJ (1996) 123IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 153: 183–190
Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P (1991) Distribution of dopaminergic receptors in the primate cerebral cortex: quatitative autoradiographic analysis using (3H)raclopride, (3H) spiperone and (3H)SCH23390. Neurosci 40: 657–671
Mager T, Dähne I, Dresel S, Pajonk F, Tatsch K, Möller HJ (1996) D2 dopamine receptor occupancy (IBZM-SPECT) and extrapyramidal symptoms under treatment with risperidone. EuroNP 6[Suppl 4]: 102
Martinot JL, Pailliere-Martinot ML, Loc’h C (1991) The estimated density of D2 striatal receptors in schizophrenia — a study with PET and 76Br Bromlisuride. Br J Psychiatry 164: 27–34
Meador-Woodruff JH (1994) Update on dopamine receptors. Ann Clin Psychiatry 6(2): 79–90
Mozley DP, Stubbs J, Kim HJ, McElgin W, Kung MP, Meegalla S, Kung HF (1996) Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J Nucl Med 37: 151–159
Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE (1995) Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 15: 2186–2191
Nestler EJ (1997) Schizophrenia: an emerging pathophysiology. Nature 385: 578–579
Nyberg S, Farde L, Halldin C, Dahl M, Bertilsson L (1996) D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152: 173–178
Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Somey A Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385: 634–636
Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, Serotonine, alpha-adrenergic and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522
Pickar D, Su TP, Weinberger DR, Coppola R, Malhotra AK, Knable MB, Lee KS, Gorey J, Bartko JJ, Breier A, Hsiao J (1996) Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. Am J Psychiatry 153: 1571–1578
Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW (1994) D2 dopamine receptor binding in the basal ganglia of antpsychotic-free schizophrenic patients. An 123I-IBZM SPECT-study Br J Psychiatry 164: 16–26
Roth RH (1984) CNS DOPAMINe autoreceptors: distribution, pharmacology and function. Ann NY Acad Sci 430: 27–53
Roth RH, Elsworth JD (1995) Biochemical pharmacology of midbrain dopamine neurons. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology, 4th edn. Raven Press, New York, pp 227–224
Seeman P, Guan HC, Van Tol HHM (1993) Dopamine D4 receptor elevated in schizophrenia. Nature 365: 441–445
Seeman P (1995) Dopamine receptors: clinical correlates. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology, 4th edn. Raven Press, New York, pp 295–302
Smiley JF, Levey AI, Ciliax BJ, Goldman-Rakic PS (1994) Dl dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant amd extrasynaptic localization in dendritic spines. Proc Natl Acad Sci 91: 5720–5724
Sunahara RK, Guan H-C, O’Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HHM, Niznik HB (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350: 614–619
Tune LE, Wong DF, Pearlson G (1992) Elevated dopamine 2 receptor density in 23 schizophrenic patients: a PET study with 11C-N-Methylspiperone. Schizophr Res 22: 147
Williams GV, Goldman-Rakic PS (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376: 572–575
Wong DF, Wagner HN, Tune LE, Dopaminnnals RF, Pearlson GD, Links JM (1986) PET reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Sci 234: 1558–1563
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Wien
About this paper
Cite this paper
Mager, T., Meisenzahl, E.M. (1998). Das dopaminerge System und schizophrene Erkrankungen. In: Möller, HJ., Müller, N. (eds) Schizophrenie — Moderne Konzepte zu Diagnostik, Pathogenese und Therapie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6471-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6471-6_8
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83086-4
Online ISBN: 978-3-7091-6471-6
eBook Packages: Springer Book Archive